Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: Overcoming cellular barriers for therapeutic gain

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 910-918

  Kalra, A V ^a   Campbell, R B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

5 fluorouracil; Drug delivery; MUC1 O glycosylation; Pancreatic cancer

Indexed keywords

CARBOHYDRATE; FLUOROURACIL; MUCIN; SIALIC ACID; SIALIDASE;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GLIOBLASTOMA; GLYCOSYLATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

ACETYLGALACTOSAMINE; ANTIMETABOLITES, ANTINEOPLASTIC; BENZYL COMPOUNDS; CA-15-3 ANTIGEN; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GLIOBLASTOMA; GLYCOSYLATION; HUMANS; MICROSCOPY, FLUORESCENCE; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 34948826922     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603972     Document Type: Article

References (37)

1. American Cancer Society, C.F.F (2007). American Cancer Society: Atlanta. 16-17
2. Beum PV, Singh J, Burdick M, Hollingsworth MA, Cheng PW (1999) Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes. J Biol Chem 274: 24641-24648
3. Byrd JC, Dahiya R, Huang J, Kim YS (1995) Inhibition of mucin synthesis by benzyl-alpha-GalNAc in KATO III gastric cancer and Caco-2 colon cancer cells. Eur J Cancer 31A: 1498-1505
4. Corfield AP, Carroll D, Myerscough N, Probert CS (2001) Mucins in the gastrointestinal tract in health and disease. Front Biosci 6: D1321-D1357
5. de Cremoux P, Extra JM, Denis MG, Pierga JY, Bourstyn E, Nos C, Clough KB, Boudou E, Martin EC, Muller A, Pouillart P, Magdelenat H (2000) Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 6: 3117-3122
6. Fishman AD, Wadler S (2001) Advances in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 1: 20-35
7. Gendler SJ, Spicer AP, Lalani E-N, Duhig N, Burchell J, Pemberton L, Boshell M, Taylor-Papadimithiou J (1991) Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Repir Dis 144: S42
8. Ho JJ, Cheng S, Kim YS (1995) Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids. Biochem Biophys Res Commun 210: 866-873
9. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS (1993) Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53: 641-651
10. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60
11. Jentoft N (1990) Why are proteins O-glycosylated? Trends Biochem Sci 15: 291-294
12. Kalra AV, Campbell RB (2006) Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm Res 23: 2809-2817
13. Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG (2006) Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 10: 689-697
14. Kigure S (2006) Immunohistochemical study of the association between the progression of pancreatic ductal lesions and the expression of MUC1, MUC2, MUC5AC, and E-cadherin. Rinsho Byori 54: 447-452
15. Kuan S-F, Byrd JC, Basbaum C, Kim YS (1989) Inhibition of mucin glycosylation by aryl-N-acetyl-galactosaminides in human colon cancer cells. J Biol Chem 264: 19271-19277
16. Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, Ozkan L, Evrensel T, Kaya E, Manavoglu O (2006) Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer. Tumori 92: 481-486
17. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA (1990) Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 265: 15294-15299
18. Lemken ML, Wolf C, Wybranietz WA, Schmidt U, Smirnow I, Buhring HJ, Mack AF, Lauer UM, Bitzer M (2007) Evidence for intercellular trafficking of VP22 in living cells. Mol Ther 15: 310-319
19. Leteurtre E, Gouyer V, Delacour D, Hemon B, Pons A, Richet C, Zanetta JP, Huet G (2003) Induction of a storage phenotype and abnormal intracellular localization of apical glycoproteins are two independent responses to GalNAcalpha-O-bn. J Histochem Cytochem 51: 349-361
20. Lukashev D, Klebanov B, Kojima H, Grinberg A, Ohta A, Berenfeld L, Wenger RH, Ohta A, Sitkovsky M (2006) Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol 177: 4962-4965
21. Moniaux N, Andrianifahanana M, Brand R, Batra SK (2004) Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 91: 1633-1638
22. Moore A, Medarova Z, Potthast A, Dai G (2004) In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 64: 1821-1827
23. Peracaula R, Tabares G, Lopez-Ferrer A, Brossmer R, de Bolos C, de Llorens R (2005) Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells. Glycoconj J 22: 135-144
24. Perey L, Hayes DF, Kufe D (1992) Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res 52: 6365-6370
25. Ruddon RW (1995) Phenotypic characteristics of cancer cells. Cancer Biology. Oxford University Press, Inc: New York
26. Sharom FJ (1997) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160: 161-175
27. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G (2003) A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452
28. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
29. Specian RD, Oliver MG (1991) Functional biology of intestinal goblet cells. Am J Physiol 260: C183-C193
30. Stonebraker JR, Wagner D, Lefensty RW, Burns K, Gendler SJ, Bergelson JM, Boucher RC, O'Neal WK, Pickles RJ (2004) Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to lumenal infection. J Virol 78: 13755-13768
31. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG (1993) Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151: 767-776
32. van Triest B, Peters GJ (1999) Thymidylate Synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 57: 179-194
33. Varki A, Diaz S (1983) A neuraminidase from Streptococcus sanguis that can release O-acetylated sialic acids. J Biol Chem 258: 12465-12471
34. Wang WC, Cummings RD (1988) The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 263: 4576-4585
35. Weckbecker G (1991) Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol Ther 50: 367-424
36. Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell- cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7: 565-577
37. Yonezawa S, Nakamura A, Horinouchi M, Sato E (2002) The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 9: 328-341